2.60HKD
2.24 BHKD
8.16 BHKD
123.13 M
About HANGZHOU TIGERMED CONSULTING CO LTD
Sector
CEO
Xiao Chun Cao
Website
Headquarters
Hangzhou
Employees (FY)
9.7 K
Founded
2004
ISIN
CNE1000040M1
FIGI
BBG00W6R5W34
Hangzhou Tigermed Consulting Co., Ltd. provides clinical research services for research and development of domestic and foreign pharmaceutical and health related products. Its services include technical services for phase I to phase IV clinical trials, registration and declaration of clinical trials, on-site services, as well as data management and analysis, etc. The company was founded on December 15, 2004 and is headquartered in Hangzhou, China.
Trade directly on the supercharts through our supported, fully-verified and user-reviewed brokers.
Frequently Asked Questions
The current price of 3347 is 31.65 HKD — it has increased by 0.96% in the past 24 hours.
Depending on the exchange, the stock ticker may vary. For instance, on HKEX exchange HANGZHOU TIGERMED CONSULTING CO LTD stocks are traded under the ticker 3347.
HANGZHOU TIGERMED CONSULTING CO LTD is going to release the next earnings report on Apr 25, 2024. Keep track of upcoming events with our Earnings Calendar.
3347 stock is 6.15% volatile and has beta coefficient of 1.77. Check out the list of the most volatile stocks — is HANGZHOU TIGERMED CONSULTING CO LTD there?
3347 earnings for the last quarter are 0.61 HKD per share, whereas the estimation was 0.77 HKD resulting in a −20.43% surprise. The estimated earnings for the next quarter are 0.52 HKD per share. See more details about HANGZHOU TIGERMED CONSULTING CO LTD earnings.
HANGZHOU TIGERMED CONSULTING CO LTD revenue for the last quarter amounts to 2.07 B HKD despite the estimated figure of 2.13 B HKD. In the next quarter revenue is expected to reach 2.04 B HKD.
Yes, you can track HANGZHOU TIGERMED CONSULTING CO LTD financials in yearly and quarterly reports right on TradingView.
3347 stock has risen by 2.76% compared to the previous week, the month change is a 4.80% rise, over the last year HANGZHOU TIGERMED CONSULTING CO LTD has showed a 57.23% decrease.
3347 net income for the last quarter is 157.01 M HKD, while the quarter before that showed 530.41 M HKD of net income which accounts for −70.40% change. Track more HANGZHOU TIGERMED CONSULTING CO LTD financial stats to get the full picture.
Today HANGZHOU TIGERMED CONSULTING CO LTD has the market capitalization of 26.80 B, it has decreased by 5.92% over the last week.
Yes, 3347 dividends are paid annually. The last dividend per share was 0.62 HKD. As of today, Dividend Yield (TTM)% is 1.96%. Tracking HANGZHOU TIGERMED CONSULTING CO LTD dividends might help you take more informed decisions.
HANGZHOU TIGERMED CONSULTING CO LTD dividend yield was 1.77% in 2023, and payout ratio reached 21.94%. The year before the numbers were 0.77% and 22.70% correspondingly. See high-dividend stocks and find more opportunities for your portfolio.
Like other stocks, 3347 shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade HANGZHOU TIGERMED CONSULTING CO LTD stock right from TradingView charts — choose your broker and connect to your account.
As of Apr 25, 2024, the company has 9.70 K employees. See our rating of the largest employees — is HANGZHOU TIGERMED CONSULTING CO LTD on this list?
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So HANGZHOU TIGERMED CONSULTING CO LTD technincal analysis shows the buy rating today, and its 1 week rating is neutral. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating HANGZHOU TIGERMED CONSULTING CO LTD stock shows the sell signal. See more of HANGZHOU TIGERMED CONSULTING CO LTD technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.
We've gathered analysts' opinions on HANGZHOU TIGERMED CONSULTING CO LTD future price: according to them, 3347 price has a max estimate of 89.62 HKD and a min estimate of 32.69 HKD. Read a more detailed HANGZHOU TIGERMED CONSULTING CO LTD forecast: see what analysts think of HANGZHOU TIGERMED CONSULTING CO LTD and suggest that you do with its stocks.
EBITDA measures a company's operating performance, its growth signifies an improvement in the efficiency of a company. HANGZHOU TIGERMED CONSULTING CO LTD EBITDA is 2.20 B HKD, and current EBITDA margin is 26.81%. See more stats in HANGZHOU TIGERMED CONSULTING CO LTD financial statements.